Gilead Sciences, Inc. has confirmed that it will be able to meet global demand for its COVID-19 antiviral therapy remdesivir by October, thanks to a rapid ramp up in its manufacturing capacity.
The US company has been investing in its own manufacturing capacity since before the US Food and Drug Administration gave...







